Treatment of Acquired Sideroblastic Anemias

Abhishek A. Mangaonkar, Mrinal M. Patnaik

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Sideroblastic anemias are a heterogeneous group of disorders unified by the presence of abnormal erythroid precursors with perinuclear mitochondrial iron deposition in the bone marrow. Based on etiology, they are classified into clonal and nonclonal. Clonal sideroblastic anemias refer to myeloid neoplasms with ring sideroblasts (RS) and frequently have somatic perturbations in the SF3B1 gene. Anemia is a major cause of morbidity in patients, and restoration of effective erythropoiesis is a major treatment goal. Morbidity includes transfusion and disease-related complications. This article focuses on treatment of acquired sideroblastic anemias and highlights areas of future investigation.

Original languageEnglish (US)
Pages (from-to)401-420
Number of pages20
JournalHematology/Oncology Clinics of North America
Volume34
Issue number2
DOIs
StatePublished - Apr 2020

Keywords

  • MDS
  • MDS-RS
  • RS
  • Ring sideroblast
  • SF3B1

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of Acquired Sideroblastic Anemias'. Together they form a unique fingerprint.

Cite this